Condition
Broader IBD news covering Crohn's disease, ulcerative colitis, research, treatments, monitoring, and patient care.
Page 46 of 88 · 4202 articles
The review highlights that colorectal IBD is under-recognized and often mistaken for infectious colitis in sub‑Saharan Africa due to limited diagnostic and specialist resources, which can delay appropriate care.
Itch is a frequent, often severe symptom in PSC that is linked to liver disease severity and worse quality of life. Recognizing and measuring pruritus matters because it significantly affects daily functioning and may...
People with ulcerative colitis face a higher colorectal cancer risk driven in part by chronic inflammation; this review explains the molecular and immune mechanisms behind that risk and highlights biomarkers and...
This preclinical study suggests a fox-derived Lactiplantibacillus plantarum strain can reduce inflammation and improve intestinal barrier markers in cell and mouse models of colitis, which could inform future...
The study links specific foods and combined dietary patterns with higher or lower odds of ulcerative colitis, which could inform patient conversations about diet and priorities for future research.
Compares widely used modelled GBD rates with population-based observations and finds they are not interchangeable for country-year estimates—important for research, surveillance, and policy that rely on these numbers.
Reliable, high-throughput lab methods are a prerequisite for therapeutic drug monitoring (TDM). For people with IBD on JAK inhibitors, validated assays can enable exposure measurement needed for future precision dosing...
In young children, enteric infections can mimic or coexist with VEO‑IBD and change imaging and clinical findings; recognizing both can affect diagnosis and treatment choices.
An uncommon oropharyngeal mass due to Crohn’s disease can be diagnostically challenging and may not respond to corticosteroids or anti-TNF therapy. For some patients, switching to a different mechanism (here, a JAK...
Population estimates help patients understand how common IBD is and show that ulcerative colitis is more common than Crohn’s in this survey. Knowing prevalence and who is more likely to be diagnosed can help people feel...
Updated FDA prescribing information affects safety monitoring and counseling for people with ulcerative colitis who take mesalamine, including children meeting the weight threshold. The label highlights kidney monitoring...
Prednisone is a commonly used systemic steroid for short-term control of IBD flares; label updates affect dosing, warnings, and official approved uses that patients and clinicians rely on.
This label update restates safety information for ROWASA (a mesalamine rectal formulation) used for distal ulcerative colitis. Patients with IBD should be aware of potential serious hypersensitivity reactions, kidney and...
Synthetic, severity-controlled endoscopic images could help researchers train and test IBD imaging algorithms and augment scarce labeled datasets, which may accelerate development of tools that interpret endoscopy for...
This update is important because tofacitinib is a JAK inhibitor approved for adults with moderately to severely active ulcerative colitis after inadequate response to TNF blockers, and the label includes major safety...
This label update affects people with IBD because tofacitinib is an approved oral JAK inhibitor for moderately to severely active ulcerative colitis and the label highlights important safety risks (infections, mortality,...
People with IBD (Crohn’s disease or ulcerative colitis) can develop vitamin K deficiency from malabsorption; this label clarifies that Vitamin K1 Injection is indicated for such situations and highlights important safety...
The FDA label defines who may be prescribed tofacitinib and highlights important safety warnings (serious infections, increased mortality signal, and malignancy risk) relevant to people with IBD and other autoimmune...
The review connects animal-model discoveries (IL-23/IL-17 and TNF pathways, gut–joint interactions) to therapies and research priorities relevant to people with SpA and IBD-associated arthritis.
Cure8 found this source from Gastroenterology, but the page could not be read reliably yet. It is tagged for Inflammatory bowel disease and Research and clinical trials. Open the original article for the full details.
Planned synthesis of global surgical rates and outcomes in the biologics era could help clinicians, patients, and researchers understand how often surgery is needed, what types of operations are performed, and common...
Preclinical research identified a plant-derived compound (polydatin) that may rebalance immune responses relevant to ulcerative colitis by targeting KEAP1–NFE2L2 signaling and reducing inflammatory T‑cell activity. This...
This study shows that people with IBD can display distinct self-care and illness-perception profiles rather than a single pattern; tailoring education and psychological support to these profiles could improve...
Patients and clinicians interested in Crohn’s disease should note a new company (Fibrx) is prioritizing drugs that directly target fibrosis and strictures — an area with few medical options today.
If validated, blood-based AI predictors of organ-specific aging might help flag organs aging faster in people with Crohn’s disease or other conditions, potentially enabling earlier monitoring or research into causes....
Recognizing eye inflammation as a possible early sign of IBD could shorten diagnostic delays and lead to earlier gastroenterology evaluation and treatment, which is especially important for children who often wait years...
This paper evaluates CAR, a simple blood‑based biomarker, in children with IBD and finds it reflects disease severity and changes over time in pediatric Crohn’s disease. That matters because reliable, easy-to-measure...
The study uses generative AI and microbiome/RNA data to search for biomarkers of intestinal fibrosis in Crohn’s disease, which could help spot scarring earlier and potentially prevent worsening complications like...
Market growth and industry activity can affect drug availability, prices, and the pace of new treatments or diagnostics reaching patients. Increased investment in biomarkers and targeted therapies may lead to better...
The paper reports a materials-based strategy to improve zinc delivery and bioavailability that reduced dose while preserving beneficial effects in a mouse colitis model—relevant because zinc supports intestinal health...
People with IBD and clinicians often face decisions about whether to stop biologics or small molecules before abdominal surgery.
The study tests whether fewer random biopsies are needed during surveillance colonoscopy with modern high-definition scopes — a question that could change how often biopsies are taken, affect procedure time, costs, and...
Early-phase trials test whether new treatments are safe and show biological activity. This study measures fecal calprotectin, a biomarker of intestinal inflammation, so it could provide early signals about whether ND-12...
People on biologic therapy who lose response often face choices: switch drugs or increase dose. This study shows that escalating doses of infliximab, adalimumab, or vedolizumab frequently led to clinical improvement and...
Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Inflammopharmacology.
This preclinical study identifies Thymosin β4 as a protective factor in intestinal inflammation and fibrosis and suggests rhTβ4 could be explored as a new therapeutic approach for IBD by targeting mineralocorticoid...
This study suggests that an intermittent fasting pattern (alternate-day fasting) increased intestinal injury, reduced immune cells, and caused anemia in a mouse model of acute colitis, implying such diets might be risky...
Identifies specific gut bacteria and fecal bilirubin metabolites that may link microbial loss to increased oxidative burden in IBD; suggests new biomarker candidates and targets for functional follow-up.
People with UC who undergo IPAA may want to know which clinical factors raise the chance of developing chronic pouchitis so they and their clinicians can plan monitoring and care. The study identifies several patient-...
The paper reports a novel small molecule (CA-23) that directly antagonizes CD28, reducing pathogenic T cell responses in preclinical IBD models and in cells from IBD donors. If validated, this represents a...
This project aims to improve prediction of autoimmune disease onset and immunotherapy-related autoimmunity by combining genetics and plasma proteins.
Researchers are testing whether IL-22 — a cytokine known to help repair gut and airway lining — could protect or heal GI tissues after SARS‑CoV‑2 infection. If true, this could point to therapies relevant to people with...
This funded NIH project investigates how EAEC and AIEC bacteria might drive intestinal inflammation by degrading MUC3A/MUC4 and disrupting receptor tyrosine kinase signaling—mechanisms that could underlie...
This pilot tests whether some patients with acute severe ulcerative colitis could avoid hospitalization by using early oral JAK inhibitor therapy plus steroids with close remote monitoring — a change that could reduce...
If successful, this approach could lower costs and simplify storage/transport of an established IBD antibody (adalimumab) and enable oral delivery, which would be relevant to people with Crohn’s disease or ulcerative...
New high-resolution, multilayer imaging tools can reveal how immune cells, epithelium, and enteric nerves interact in the intestine—processes central to IBD, colorectal cancer risk, and gut-brain disorders.
Researchers are exploring whether transferring younger gut microbiomes could slow aging and prevent age-related diseases. If validated, the work could point to microbiome-based therapies that affect systemic health,...
Researchers are using a new MRI-based index (ANDI) to look for early brain changes linked to Parkinson’s disease and dementia in groups at higher risk, including people with inflammatory bowel disease. If successful, the...
